Biblio
Export 751 results:
[ Author] Title Type Year Filters: First Letter Of Keyword is P [Clear All Filters]
“What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
, “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
, “What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?”, J Alzheimers Dis, vol. 51, no. 3, pp. 793-800, 2016.
, “Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?”, J Alzheimers Dis, vol. 61, no. 1, pp. 47-52, 2018.
, “Self-Consciousness in Patients with Behavioral Variant Frontotemporal Dementia.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1021-9, 2016.
, “Self-Consciousness in Patients with Behavioral Variant Frontotemporal Dementia.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1021-9, 2016.
, “Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial.”, J Alzheimers Dis, vol. 88, no. 1, pp. 75-95, 2022.
, “Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1191-203, 2016.
, “Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1191-203, 2016.
, “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
, “Impact of Hearing Aids on Progression of Cognitive Decline, Depression, and Quality of Life Among People with Cognitive Impairment and Dementia.”, J Alzheimers Dis, vol. 92, no. 2, pp. 629-638, 2023.
, “Heterogeneity of Cognitive Anosognosia and its Variation with the Severity of Dementia in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 89-99, 2016.
, “Heterogeneity of Cognitive Anosognosia and its Variation with the Severity of Dementia in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 89-99, 2016.
, “Heterogeneity of Cognitive Anosognosia and its Variation with the Severity of Dementia in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 1, pp. 89-99, 2016.
, “Impact of Social Isolation on People with Dementia and Their Family Caregivers.”, J Alzheimers Dis, vol. 81, no. 2, pp. 607-617, 2021.
, “Impact of Social Isolation on People with Dementia and Their Family Caregivers.”, J Alzheimers Dis, vol. 81, no. 2, pp. 607-617, 2021.
, “COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences.”, J Alzheimers Dis, vol. 88, no. 2, pp. 399-416, 2022.
, “Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings.”, J Alzheimers Dis, vol. 50, no. 2, pp. 465-76, 2016.
, “Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings.”, J Alzheimers Dis, vol. 50, no. 2, pp. 465-76, 2016.
, “The Impact of Music on the Self in Dementia.”, J Alzheimers Dis, vol. 61, no. 3, pp. 827-841, 2018.
, “Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.”, Neuron, vol. 74, no. 3, pp. 467-74, 2012.
, “Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.”, Neuron, vol. 74, no. 3, pp. 467-74, 2012.
, “Cognitive Stimulation Modulates Platelet Total Phospholipases A2 Activity in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 4, pp. 957-62, 2016.
, “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
, “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
,